DTIL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Precision BioSciences Inc (DTIL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential in its gene-editing pipeline, supported by positive analyst ratings and recent clinical trial expansion. Despite short-term price fluctuations, the company's long-term prospects and market positioning make it a compelling investment opportunity.
The technical indicators show a bullish trend with MACD positively expanding above zero, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the stock trading near its first resistance level (R1: 7.458). RSI is neutral, indicating no overbought or oversold conditions.
Approval to expand the ELIMINATE-B trial into France and Romania, increasing patient enrollment for the PBGENE-HBV clinical trial.
Analysts have initiated coverage with a 'Buy' rating and a $30 price target, citing the company's underappreciated gene-editing potential.
Recent price decline in pre-market (-2.61%), regular market (-1.70%), and post-market (-0.40%).
Financials show a significant drop in net income (-213.46% YoY) and EPS (-147.30% YoY) in Q4 2025.
In Q4 2025, revenue surged by 5261.13% YoY to $34.2 million, indicating strong top-line growth. However, net income dropped by -213.46% YoY, and EPS fell by -147.30% YoY, reflecting profitability challenges. Gross margin remained stable at 100%.
JonesResearch initiated coverage with a 'Buy' rating and a $30 price target, highlighting the company's potential in gene-editing therapies for hepatitis B and Duchenne muscular dystrophy.
